Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)
Company News
Can-Fite BioPharma's drug Namodenoson has shown promising results in treating liver cancer, as well as providing protective effects on the heart, liver, and nervous system, unlike traditional chemotherapy. The study highlights Namodenoson's ability to increase adiponectin levels, a key cytokine known to drive multi-organ protective effects.
Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.
Penny stocks to watch this week. The post 3 Top Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page HC Wainwright & Co. cut Can-Fite BioPharma Ltd. (NYSE: CANF) price target from $34 to $18. HC Wainwright & Co. analyst Vernon Bernardino maintained a Buy rating. Can-Fite BioPharma shares fell 6.8% to close at $1.92 on Monday. See how other analysts view this stock. Barclays slashed the price target for Arvinas, Inc. (NASDAQ: ARVN) from $39 to $26. Barclays analyst Peter Lawson maintained an Overweight rating. Arvinas shares closed at $14.55 on Monday. See how other analysts view this stock. Fermium Research lowered FMC Corporation (NYSE: FMC) price target from $85 to $62. Fermium Research analyst Frank Mitsch maintained a Hold ...